| pubmed-article:9025780 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9025780 | lifeskim:mentions | umls-concept:C0231335 | lld:lifeskim |
| pubmed-article:9025780 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:9025780 | lifeskim:mentions | umls-concept:C0007257 | lld:lifeskim |
| pubmed-article:9025780 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9025780 | pubmed:dateCreated | 1997-2-27 | lld:pubmed |
| pubmed-article:9025780 | pubmed:abstractText | Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors. This agent exhibits a steep dose-response curve in in vitro and animal tumor models and has been proposed for use in high-dose chemotherapy as a single agent or in combination. We conducted a phase II study to assess high-dose BCNU in children with high-grade gliomas. A total of 13 children with high-grade gliomas were treated in a phase II study using high-dose BCNU (800 mg/m2) followed by autologous bone marrow transplantation. Eight patients were newly diagnosed, and five were treated at the time of tumor recurrence. Seven patients had diffuse intrinsic brain-stem gliomas. The response was assessed at 1 month after treatment. Only one objective effect was observed. Five patients had stable disease and seven progressed. The immediate toxicity was mild; however, one patient developed fatal respiratory distress at 50 days after treatment with high-dose BCNU. Dose escalation of BCNU does not seem beneficial in children with high-grade gliomas. | lld:pubmed |
| pubmed-article:9025780 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9025780 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9025780 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9025780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9025780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9025780 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9025780 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:9025780 | pubmed:author | pubmed-author:BironPP | lld:pubmed |
| pubmed-article:9025780 | pubmed:author | pubmed-author:Brunat-Mentig... | lld:pubmed |
| pubmed-article:9025780 | pubmed:author | pubmed-author:PhilipTT | lld:pubmed |
| pubmed-article:9025780 | pubmed:author | pubmed-author:PhilipII | lld:pubmed |
| pubmed-article:9025780 | pubmed:author | pubmed-author:BouffetEE | lld:pubmed |
| pubmed-article:9025780 | pubmed:author | pubmed-author:KhelfaouiFF | lld:pubmed |
| pubmed-article:9025780 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9025780 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:9025780 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9025780 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9025780 | pubmed:pagination | 376-9 | lld:pubmed |
| pubmed-article:9025780 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:meshHeading | pubmed-meshheading:9025780-... | lld:pubmed |
| pubmed-article:9025780 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9025780 | pubmed:articleTitle | High-dose carmustine for high-grade gliomas in childhood. | lld:pubmed |
| pubmed-article:9025780 | pubmed:affiliation | Pediatric Department, Centre Léon Bérard, Lyon, France. | lld:pubmed |
| pubmed-article:9025780 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9025780 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9025780 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9025780 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9025780 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9025780 | lld:pubmed |
